PRINCETON, N.J. --(BUSINESS WIRE)--Dec. 6, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 35 new
Favorable long-term durability data further supports JELMYTO as a primary treatment for low-grade upper tract urothelial cancer PRINCETON, N.J. --(BUSINESS WIRE)--Dec. 5, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions
UGN-102 demonstrated 82.3% duration of response (DOR) at 12 months in patients who achieved complete response at 3 months 79.6% complete response rate at 3 months in patients treated with UGN-102 Safety profile consistent with prior clinical trials of UGN-102 PRINCETON, N.J. --(BUSINESS WIRE)--Dec.
PRINCETON, N.J. --(BUSINESS WIRE)--Dec. 2, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that new data on UGN-102 (mitomycin) for intravesical solution,
The Study Results are Published in the Journal of Urology Online PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 26, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights results
New Drug Application for UGN-102 accepted by US FDA ; PDUFA target action date set for June 13, 2025 JELMYTO ® achieved net product sales of $25.2 million in Q3 2024, compared to $20.9 million in Q3 2023 $254.2 million in cash, cash equivalents and marketable securities as of September 30, 2024
Fireside Chat on November 12, 2024 at 3:00 PM ET PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 5, 2024-- UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will
Conference Call and Webcast Scheduled for Wednesday, November 6, 2024 , at 10:00AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Oct. 30, 2024-- UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
The Kaplan-Meier Estimate of Duration of Response at 12 Months in Patients Who Achieved a Complete Response at Three Months was 82.3% Patients Receiving UGN-102 had a 79.6% Complete Response Rate at Three Months Side Effect Profile Consistent with Previous Clinical Trials of UGN-102 PRINCETON, N.J
PDUFA goal date set for June 13, 2025 UGN-102 would be the first FDA-approved medicine for LG-IR-NMIBC, if approved PRINCETON, N.J. --(BUSINESS WIRE)--Oct. 15, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat
